Physician profile
Michael D Silvas
NPI 1689774556
$828.59
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $112 · 2021: $282 · 2022: $252.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $238.83 | 2019-2022 | |
| Abbvie INC. | $104.86 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $57.11 | 2020-2021 | |
| Pfizer INC. | $51.74 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $47.46 | 2019-2022 | |
| Novo Nordisk INC | $38.87 | 2022 | |
| Lilly USA, LLC | $36.63 | 2021-2022 | |
| Shire North American Group INC | $32.89 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $29.67 | 2021 | |
| Amgen INC. | $25.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.09 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.72 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $23.00 | 2019 | |
| Daiichi Sankyo INC. | $22.62 | 2021 | |
| Sanofi Pasteur INC. | $19.25 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $18.89 | 2019 | |
| Abbott Laboratories | $17.42 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Silvas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.